Spiromacrocyclic compounds acting as orexin OX2 receptor agonists have been described in an H. Lundbeck A/S patent and reported to be useful for the treatment of type 1 and type 2 narcolepsy.

Daiichi Sankyo Co. Ltd. has prepared and tested new 2-azabicyclo[3.1.1]heptane compounds acting as orexin OX2 receptor agonists with potential for the treatment of narcolepsy.

Takeda Pharmaceutical Co. Ltd. has discovered orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, among others.

Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy.

Takeda Pharmaceutical Co. Ltd. has discovered orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy.

Kissei Pharmaceutical Co. Ltd. has divulged orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy.

Harmony Biosciences Holdings Inc. has announced an exclusive licensing agreement with Bioprojet Pharma SAS to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin OX2 receptor agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.